Abstract
Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Current Molecular Medicine
Title:Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?
Volume: 15 Issue: 10
Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti
Affiliation:
Keywords: Relapsing/remitting multiple sclerosis, first diagnosis patients, Wnt/β-catenin pathway, natalizumab, interferon-beta, neurodegenerative disease.
Abstract: Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.
Export Options
About this article
Cite this article as:
Galuppo M., Mazzon E., Giacoppo S., Bereshchenko O., Bruscoli S., Riccardi C. and Bramanti P., Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?, Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114825
DOI https://dx.doi.org/10.2174/1566524016666151123114825 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Role of Nitric Oxide and Reactive Oxygen Species in Arthritis
Current Pharmaceutical Design Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics Up-Regulation of Gr1+CD11b+ Population in Spleen of Dextran Sulfate Sodium Administered Mice Works to Repair Colitis
Inflammation & Allergy - Drug Targets (Discontinued) Review of the Methods to Obtain Paediatric Drug Safety Information: Spontaneous Reporting and Healthcare Databases, Active Surveillance Programmes, Systematic Reviews and Meta-analyses
Current Clinical Pharmacology Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Current Molecular Medicine Role of Lipopolysaccharides in Potential Applications of Nanocarrier Systems
Current Pharmaceutical Design The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation